Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial

BACKGROUND

The Coronavirus Disease 2019 (COVID-19) pandemic has infected more than forty million people and has resulted in more than a million deaths worldwide. In the absence of an effective prophylactic vaccine, there is a dire need for finding effective treatments for COVID-19 patients. At a minimum, an ideal treatment should expedite symptomatic recovery, decrease viral transmission in the community with earlier viral clearance in the infected patients, and reduce mortality. In this context, treatments including hydroxychloroquine/azithromycin, lopinavir-ritonavir, remdesivir, dexamethasone, convalescent plasma and antibody therapies have shown some efficacy.^1-4 However, there is still a long way to go before we have an effective treatment regimen for COVID-19. To this end, we have conducted a clinical trial in which we have investigated the potential efficacy of a combination of honey and Nigella sativa (HNS) in treating COVID-19 patients.

Both components of HNS have anti-viral, anti-microbial, anti-inflammatory and immune-modulatory effects with proven safety profiles. ^5-8 The beneficial effects of honey against different viruses including rubella virus, Herpes Simplex virus, Hepatitis virus, and Varicella-Zoster virus have been reported earlier.⁶ Moreover, in-silico molecular docking studies have shown that six flavonoid compounds from honey might inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication by binding to the viral 3-chymotrypsin-like-cysteine protease.⁹ Honey also has strong antibacterial activity against clinically important gram-positive bacteria (methicillin-resistant Staphylococcus aureus) and gram-negative bacteria (Pseudomonas aeruginosa, Enterobacter spp, and Klebsiella). Additionally, honey has shown synergism with other antibiotics like oxacillin, tetracycline, imipenem and meropenem.⁶ The use of honey not only improves the proliferation of T and B lymphocytes, but also their phagocytic activity. It additionally inhibits the expression of vital pro-inflammatory cytokines such as interleukin (IL) 1 beta and IL-6. Lymphocyte-mediated antiviral activity has proven to be poorly effective against COVID-19, especially considering the exaggerated release of pro-inflammatory mediators despite lymphocytopenia. Thus, honey is postulated to play a pivotal role in fighting COVID-19.¹⁰ Its’ use has shown to be more beneficial in upper respiratory tract infections than usual care especially in the context of cough frequency and severity.¹¹

Nigella sativa (NS), a widely used medicinal plant of the family Ranunculaceae and commonly known as Black Cumin/Kalonji, has shown to exert antiviral effects against various viruses such as human immunodeficiency virus and hepatitis C virus.¹² It has also shown to decrease the replication of SARS-CoV in-vitro in cell cultures.¹³ Molecular docking studies have shown that some of its’ components such as nigelledine, α-hederin and thymoquinone have high affinity with several SARS-CoV-2 enzymes and proteins. In fact, they exhibit an energy complex score better than that of chloroquine, hydroxychloroquine and favipiravir – the drugs that have shown some anti-SARS-CoV-2 activity. NS has shown antibacterial properties against many bacteria including drug sensitive and resistant S. aureus, P. aeruginosa, Helicobacter pylori, and Escherichia coli. Moreover, NS has shown synergism with streptomycin and gentamycin. It also demodulates the secretion of a number of pro-inflammatory mediators and improves helper-T cell (T4) and suppressor-T-cell (T8) ratio with increased natural killer (NK) cell activity. It also manifests potential radical scavenging.^{14, 15}

As honey and Nigella sativa exhibit overlapping pharmacological profiles, we reasoned that the combination could be more effective in mitigating severity of the disease, controlling viral replication and curing COVID-19 patients. The combination has been used successfully in various disease conditions.^16-18 We report here that the HNS treatment results in earlier recovery and viral clearance in COVID-19 patients.

METHODOLOGY

PROCEDURE

The HNS group received honey (1 gm) plus encapsulated Nigella sativa seeds (80 mg) per kg body weight orally in 2-3 divided doses daily for up-to 13 days while the control group received placebo (empty capsules). Both the products were certified for purity by botany department of Government College University, Lahore, Pakistan. Additionally, each patient in the trial received standard care therapy (SCT) as recommended by the treating physician and the clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan. SCT primarily comprised of antipyretics, antibiotics, anticoagulants, steroids, supplemental oxygen and mechanical ventilation. The study participants were assessed for clinical symptoms daily by an on-site investigator for 13 days. During the study, when a patient recovered and remained asymptomatic for 48 h, he/she underwent a second SARS-CoV-2 RT-PCR test within the next 48 h (Figure 1). If the patient tested negative, they were deemed to have cleared the infection and their treatment stopped. In case of a positive test, a third PCR test was performed on day 14 with no further follow-up. A clinical grading score (CGS) was recorded for each patient on day 0, 4, 6, 8, 10 and 12. It was based on a seven-point ordinal scale: grade 1 (not hospitalized, no evidence of infection and resumption of normal activities), grade 2 (not hospitalized, but unable to resume normal activities), grade 3 (hospitalized, not requiring supplemental oxygen), grade 4 (hospitalized, requiring supplemental oxygen), grade 5 (hospitalized, requiring nasal high-flow oxygen therapy and/or noninvasive mechanical ventilation), grade 6 (hospitalized, requiring ECMO and/or invasive mechanical ventilation) and grade 7 (death). This scale has previously been used as end point in clinical trials in COVID-19 patients.² Severity of symptoms was categorized as mild disease including patients with mild symptoms of COVID-19 but no radiological evidence of pneumonia. Moderate disease included patients with hypoxia (oxygen saturation <94% but >90%) or chest X-ray with infiltrates involving <50% of the lung fields or fever, cough, sputum production, and other respiratory tract related symptoms. Severe disease was defined as the presence of SaO₂/SpO₂ below 90% on room air or a PaO₂ to FiO₂ ratio of 300 or lower or radiological evidence showing more than 50% lungs involvement. Body temperature was measured, and fever was graded as no fever (98-99 °F), mild (>99-<100 °F), moderate (100-101.9 °F) and severe (≤102°F). The cough was classified as mild (occasional but transient cough), moderate (frequent but slightly influencing daytime activities) and severe (frequent cough but significantly influencing daytime activities). The shortness of breath was categorized as Grade1 (not troubled by breathlessness except on strenuous exercise), grade 2 (Short of breath when hurrying on the level or walking up a slight hill), grade 3 (walks slower than most people on the level, stops after a mile or so, or stop after 15 minutes walking at own pace), grade 4 (tops for breath after walking about 100 yards or a few minutes on level ground) and grade 5 (too breathless to leave the house, or breathless when undressing). Myalgia and “how sick do you feel” were subjective feeling assessed on 10-point chart and classified as mild, moderate and severe. Serum C-reactive Protein (CRP) levels were measured by ELISA kit (Invitrogen, USA). Safety outcomes including adverse events were categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Laboratory investigations were assessed as a part of the protocol as per recommendations of the treating physician. The trial steering committee monitored trial safety. For patients who were discharged before day 13 or were home-quarantined, follow-up was done by telemedicine.

• Download figure
• Open in new tab

Figure 1: Study Flow Chart.

Team A: Responsible for the recruitment and SARS-CoV-2 RT-PCR testing; Team B: Daily evaluated degree of fever, cough, myalgia, shortness of breath, oxygen therapy, “how sick do you feel” and rate emotional status; Team C: Reported clinical grading scale (CGS) on seven-point ordinal scale assessment as 0, 4, 6, 8, 10 and 12 days; Team D conducted follow-up PCR and CRP determinations.

RESULTS

Two thousand five hundred and twenty-three suspected COVID-19 patients were screened from April 30, to July 29, 2020, in which 1046 patients tested positive for the SARS-CoV-2 nucleic acid. Of these participants, 313 met the inclusion criteria (Figure 1). The spectrum of their clinical symptoms was stratified into two groups: moderate and severe. The two groups comprised of 210 and 103 patients, respectively. The patients within each of the two groups were randomly assigned to the treatment and control groups. The number of patients in moderate control, moderate HNS, severe control and severe HNS were 103, 107, 53, and 50, respectively. Their baseline demographics with clinical and laboratory parameters are shown in Table 1. Paracetamol and azithromycin were the top two prescribed drugs as part of the SCT. Two patients opted for home quarantine despite needing oxygen therapy.

PRIMARY OUTCOMES

Primary outcomes are shown in Table 2. Alleviation of COVID-19 symptoms for patients in the HNS groups occurred earlier than control groups: 4 versus 7 days for the moderate patients (HR: 6.11; 95% CI: 4.23-8.84; P<0.0001) and 6 versus 13 days for the severe disease patients (HR: 4.04; 95% CI: 2.46-6.64; P<0.0001). Viral clearance (being negative for the SARS-CoV-2 RT-PCR test) occurred 4 days sooner in the HNS group for both moderate (HR: 5.53; 95% CI: 3.76-8.14; P<0.0001) and severe cases (HR: 4.32; 95% CI: 2.62-7.13; P<0.0001). The Kaplan-Meier curves for these variables are shown in Figure 2. In moderate patients, the HNS group resumed earlier while control group was unable to resume daily life activities as evident by the lower median CGS at day 6 (odds ratio: 0.07; 95% CI: 0.03-0.13; P<0.0001). Meanwhile, in severe groups, the HNS cases were discharged from the hospital, whereas the control cases were still hospitalized on supplemental oxygen as per median CGS at day 6 (Odds Ratio: 0.03; 95% CI: 0.01-0.09; P<0.0001).

View this table:

• View inline
• View popup

Table 2. Primary and Secondary Outcome (Intention-to-Treat Population) *

• Download figure
• Open in new tab

Figure 2. Kinetic changes in outcomes.

A. Mean oxygen saturation spO2 over time in severe cases; Kaplan-Meier probability curves for time taken (in days) for alleviation of symptoms in moderate (B) and severe cases (C); Kaplan-Meier probability curves for time taken (in days) for vial clearance in moderate (D) and severe cases (E).ns = non-significant, *= P<0.05, **=P<0.001, ***=P<0.0001.

SECONDARY OUTCOMES

There were significant differences in all secondary outcomes between the treatment and control groups (see Table 2 for secondary outcomes). In moderate COVID-19 patients, the degree of fever (median) was 100-101.9°F (moderate) in the control group while HNS arm participants were afebrile on day 4 (OR: 0.05; 95% CI: 0.03-0.1; P <0.0001). A significant reduction in the degree of fever was observed in severe cases on day 4 (OR: 0.21; 95% CI: 0.09-0.46; P=0.0001). CRP levels decreased significantly on day 6 in both the HNS groups compared with their respective control groups (moderate 6.15 ± 2.45 versus 9.44 ± 4.94 mg/L, P <0.0001 and severe cases 15.83 ± 7.17 versus 23.32 ± 8.73 mg/L, P <0.0001). On day 8, as per the median degree of symptoms severity, 98.13% patients were asymptomatic in HNS treated moderate cases compared to 56.31% in the control group (OR: 0.009; 95% CI: 0.001-0.08; P<0.0001). Similarly, in severe cases, more patients became asymptomatic in the HNS group in severe cases while a higher number had moderate symptoms (median) in the control arm (OR: 0.1; 95% CI: 0.04-0.24). By day 10, 96.26% of the moderate cases patients fully resumed normal activities with HNS compared to 68.93% in the control group (OR: 0.07; 95% CI: 0.02-0.21). For the severe group, the median CGS at day 10 revealed that mostly HNS group cases resumed normal activities while control patients were still hospitalized requiring oxygen therapy (OR:0.05; 95% CI: 0.02-0.15). The distribution of patients in the ordinal-scale categories over time is shown in Figure 3. Thirty-day mortality was 18.87% in the control group and 4% with HNS therapy (OR: 0.18 95% CI: 0.02-0.92).

• Download figure
• Open in new tab

Figure 3. Kinetics of clinical status grading in Ordinal-Scale in COVID-19 patients.

The Figure shows kinetic changes in clinical grade score (in 7-point ordinal-scale) in COVID-19 patient receiving the treatment (HNS) or placebo (Control). Note increases numbers of patients within scale 1 in the HNS group both for the moderate and severe cases.

DISCUSSION

The study was a multicenter, randomized, placebo-controlled clinical trial investigating the therapeutic efficacy of HNS against COVID-19. To the best of our knowledge, this trial is the first of its’ kind in which a combination of two natural substances were investigated. Current study showed superior efficacy of HNS for COVID-19 in most of the studied outcomes. In control groups, about half of the patients required a 2-fold higher duration to become asymptomatic compared to those in the HNS groups. Similarly, in >50% of the participants, viral clearance occurred 4-5 days earlier in HNS groups, as tested by PCR. Mean oxygen saturation above 90%, in severe cases, was achieved 6 days earlier with HNS treatment (Figure 2). In the group of moderate cases, by day 4, more than half of participants (HNS group) became afebrile while control group patients persisted with a moderate fever. Furthermore, among severe cases 22% (versus 3.77%) of patients touched the baseline temperature. By day 6, among moderate cases, majority of the patients resumed normal daily activities in the HNS group compared to limited activities in the control group. Meanwhile, among severe cases, the majority of patients were discharged in HNS groups while control group participants were still hospitalized requiring oxygen therapy. On day 8, among moderate and severe cases, 98.13% (versus 56.31%) and 70% (versus 19.61%) became asymptomatic with HNS treatment, respectively. The mortality rate was ∽4 times higher in the control group. All data combined, is suggestive of a robust therapeutic profile of HNS and results can be highly encouraging amidst current second wave of SARS-CoV-2 infection. This superior efficacy of HNS is attributed to the combination of its several constituents.

Unlike other antivirals that target a specific structure or pathway of SARS-CoV-2 infection, HNS might kill/inhibit the virus through a multiprong strategy by targeting numerous viral sites or host-virus interactions. For example, in-silico and in-vitro studies predicted that multiple flavonoid and phenolic compounds present in HNS such as kaempferol, hesperidin’s, chrysin, quercetin and linoleic acid docked/bound to the SARS-CoV-2 spike protein–human Angiotensin Converting Enzyme-2 receptor (a receptor for spike protein binding of novel coronavirus) complex.^19,20 Among the flavonoids in HNS, of particular interest is quercetin which is being investigated in many clinical trials against COVID-19. Other than quercetin’s predicted binding to the viral-human protein junction, it is also known to possess antibacterial properties by disrupting membranes, transport, and motility. HNS also contains Zinc, which has established antiviral properties against several viruses via inhibiting viral replication and acting as an immuno-modulatory agent.²¹ Till-date thirty-eight clinical trials are underway to test the efficacy of Zinc as an effective anti-COVID-19 agent. Another constituent of HNS is ascorbic acid (vitamin C), a common antioxidant and free radical scavenger with anti-inflammatory properties that reduces mediators such as IL-6 and endothelin-1. It also has proven antimicrobial and immunomodulatory properties and block several key components of cytokine storms.^22,23 To this end, forty-five clinical trials have been registered using ascorbic acid to test its therapeutic benefit as prophylaxis and adjunctive medical therapy against COVID-19, thus far. Thus, HNS contains a cocktail of phytochemicals that complement one another to tackle SARS-CoV-2 related disease pathologies. For instance, quercetin is a zinc ionophore and their synergism with vitamin C against SARS-CoV-2 is suggested.²⁴ Quercetin has also shown to inhibit pro-inflammatory cytokine responses (by reducing MHC class-II antigen presentation and TLR-signaling from activated dendritic cells) while stimulating T-helper 1 and cytotoxic-CD8 pathway for adequate viral clearance. Moreover, these processes are further enhanced by the presence of Zinc, thus potentiating each other in a coordinated fashion.¹⁹ In an in-vitro study, linoleic acid (flavonoid) has also shown synergy with the COVID-19 drug remdesivir, suppressing SARS-CoV-2 replication.²⁰

Honey is mainly comprised of sugars with small amounts of amino acids, proteins, enzymes, organic acids, vitamins, minerals, volatile substances, and polyphenols. The antibacterial features of honey have been attributed to high sugar concentration, hydrogen peroxide (H₂O₂) and low pH along with methylglyoxal and the antimicrobial peptide bee defensin-1. The presence of H₂O₂ within honey irreversibly damages microbial DNA through the generation of hydroxyl radicals.⁵ Moreover, honey promotes lymphocyte proliferation, stimulates phagocytosis, and regulates the pro-inflammatory cytokine production. Some constituents (for instance, type II arabinogalactans, methylglyoxal, and the major royal jelly protein-1) cause immunostimulatory or pro-inflammatory action via stimulating the production of immunological mediators like tumor necrosis factor α (TNF-α), IL-1β, and IL-6. On the other hand, some components (like glucose oxidase, gluconic acid, MGO, and polyphenols) show anti-inflammatory action via suppression of the production of certain molecules, like matrix metalloproteinases, and reactive oxygen species.⁶

The active principles in NS include thymoquinone (TQ), thymohydroquinone, dithymoquinone, thymol, carvacrol, nigellicine, nigellidine, and -hedrin. However, one of the integral components of Nigella sativa seeds is TQ with hydrophobicity and relatively smaller size that can easily pass-through infected cells’ plasma membranes. As it transits to the infected cells, TQ can bind to the lipophilic envelope of the SARS-CoV-2 virus due to its hydrophobic nature and, thus, destroy it before entering the cells. It exhibits its’ antibacterial potential especially by inhibiting biofilm synthesis in some bacteria. It has shown its’ antioxidant property via induction of the expression and/or activity of glutathione-S-transferase, glutathione peroxidase, superoxide dismutase and glutathione reductase.⁷ It modulates or inhibits inflammatory responses e.g., IL-1, IL-6, IL-10, IL-18, TNF-α, and nuclear factor-κB, hence, can significantly lower the chances of cytokine storm related COVID-19 mortality.²⁵

The anti-diabetic, anti-hypertensive, cardio-protective and broncho-dilatory properties of HNS might make it even more beneficial in diabetic, hypertensive, cardiac and asthmatic patients which have a higher COVID-19 associated mortality.^12,26 Furthermore, anti-platelet and anti-coagulant effects of HNS may also shield COVID-19 patients from thromboembolic complications, which are among the leading complications and causes of mortality.²⁷ The hepato- and reno-protective nature of HNS may offer added precedence over other drugs in limiting COVID-19 related hepatic and renal injuries.^12,26 Anti-pyretic, analgesic and antitussive properties of HNS can also provide symptomatic relief.¹¹ Furthermore, HNS’s antimicrobial properties and synergism with other antibiotics against superimposed infections might prevent sepsis-related deaths.^6,8,14 NICE and Public Heath England guidelines also recommend honey as the first line of treatment for an acute cough caused by upper respiratory tract infections, known as one of the defining symptoms of COVID-19. These findings strengthen the use of HNS as a potential candidate for combating SARS-CoV-2 worldwide.

In comparison to this, the recovery time reported for remdesivir was 10 days versus 15 days for the control (P<0.001),³ whereas lopinavir-ritonavir resulted in no decrease in the recovery time (16 days versus 16 days; P=0.09).² In our study, in ∼50% of cases, SARS-CoV-2 RT-PCR became negative 4 days sooner in HNS groups than control groups. In previous studies, mortality among severe cases in comparison to control group was 27.0% (versus 25.0%) for hydroxychloroquine,¹ 19.2% (versus 25.0%) for lopinavir-ritonavir,² 15.7% (versus 24.0%) for convalescent plasma,²⁸ 11.4% (versus 15.2%) for remdesivir,³ 22.9% (versus 25.7%) for dexamethasone,⁴ and only 4% (versus 18.87%) for HNS. Thus, HNS provided clinical superiority in reducing mortality in COVID-19 patients. Of note, combined mortality data provided by Solidarity and ACTT-1 for remdesivir and by Solidarity and Recovery trial for lopinavir-ritonavir failed to provide statistical improvement in mortality.²⁹ In contrast to these drugs, HNS represents a safer and more affordable option that can be used as an in-house remedy.

A major limitation of this study was that the honey and NS were not administered as treatments to the patients separately. Patients on ventilator support were not enrolled in this study. A multinational study with a larger sample size is required to investigate potential variations in responses to the treatment in COVID-19 patients from different racial and ethnic origins.

CONCLUSION

In conclusion, HNS has proven itself a safe and effective remedy for COVID-19 patients. It promotes viral clearance, quicker recovery and reduces mortality. Its affordability (< $5 for the whole treatment course), over the counter availability and ease of administration (as an easy home-based remedy) make this treatment even more feasible. Furthermore, as an inexpensive nutraceutical, HNS can be used alone or in combination with other drugs for additive effects. The treatment is very likely to reduce burden on health care systems in a significant manner.

Research in context

AUTHORS’ CONTRIBUTIONS

SA and ShA contributed equally to this paper and share joint first authorship. TM, QAS, AA, MA, and MI are senior authors. MA, MAI, LK, UNS, and IF were co-chief authors of this draft. SA, MAI, AA and MA contributed to conception, designing, acquisition of data, manuscript drafting and intellectual input. SA and MoA proposed the hypothesis and study design and obtained the funding. RA, MSS, KH, HR and ABA added the research delivery to the study centers. MA, MoA, SiA and MFN contributed biochemical, pharmacological and pharmaceutical inputs along with dosimetry. MKA, SoA, MAz and HZ led the development of data cleaning and analysis and took responsibility for the results in this draft and future analysis. SA, MoA, RA and AH drafted the first version of the manuscript. NM, IF, SR, AbH, ZA, AK, ZH, ShaA, HR, ABA, KH and AAr represented the conduction and validation of the data compilation and analysis in the manuscript. KN, MSu, SZ, IA, AH, AM, TM, SS, MeA, AA, MA, QAS and MI has overlooked the conduction and validity of the trial along with contributed to intellectual inputs in study protocol and methodology along with final manuscript write up. MeA and MI made sure validity of the data collection, data analysis and ethical considerations in their institutes. All authors are responsible for their contributions, providing critical edits and final authorization of the article. The corresponding author attest the authenticity of that all listed authors meet authorship criteria.